Dasatinib (Sprycel®) is recommended as an option for use within NHS Wales for the treatment of paediatric patients weighing ≥ 10 kg with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in chronic phase (Ph+CML-CP) or Ph+CML-CP resistant or intolerant to prior therapy including imatinib. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.